Tesamorelin Research Guide — What Studies Show (2026)
⚠️ Research Use Only. This post is educational and does not constitute medical advice. All peptides discussed are sold for research purposes only. See our full disclaimer.
Overview
Tesamorelin is an FDA-approved GHRH analog studied extensively for visceral fat reduction and metabolic health.
What is Tesamorelin?
Tesamorelin sits in an unusual position among research peptides — it's the only GHRH analog with full FDA approval for a human indication. It was approved in 2010 under the trade name Egrifta for the treatment of HIV-associated lipodystrophy, specifically for reducing visceral adipose tissue.
Mechanistically, Tesamorelin is a 44-amino-acid synthetic analog of human GHRH with an added trans-3-hexenoic acid group that prevents enzymatic degradation. It binds GHRH receptors in the anterior pituitary and triggers pulsatile growth hormone release that mirrors natural physiology.
Clinical trials in HIV patients showed roughly 15-18% reductions in visceral adipose tissue over 26 weeks at the standard 2 mg/day dose. Subsequent research has examined Tesamorelin in cognitively impaired older adults, with one randomized trial showing improvements in executive function correlated with IGF-1 changes.
Tesamorelin's research profile is more substantial than most peptides on this list because of its clinical approval pathway. The trade-off is that GHRH analogs share the same long-term concerns: potential insulin resistance, fluid retention, and IGF-1 elevation that warrants periodic monitoring. Research protocols vary widely in dose and duration.
Top Research Uses
- Visceral fat reduction
- Growth hormone stimulation
- Lipid profile improvement
- Cognitive function research
- Body composition
Mechanism of Action
Synthetic GHRH analog that stimulates pulsatile GH release from the anterior pituitary
Research Parameters
| Half-Life | ~26-38 minutes (parent), but downstream GH/IGF-1 effects last hours |
| Typical Research Dose | Clinical research used 2 mg/day subq; lower research doses commonly cited |
| Administration Route | Subcutaneous |
| Reported Side Effects | Injection site reactions, arthralgia, peripheral edema, possible glucose intolerance with extended use |
Dosing ranges cited from published research literature. These are not recommendations for human use. Tesamorelin is a research compound — not for human consumption.
Research Strength: High
Tesamorelin has a substantial body of preclinical research supporting its studied applications. Multiple independent studies have examined its mechanisms and effects in animal models.
Vendor & Sourcing Notes
Pharmaceutical-grade Tesamorelin is FDA-approved as Egrifta; research-grade powder also available
Always request third-party HPLC purity reports and mass spectrometry verification when sourcing research peptides. Quality varies significantly between suppliers.
Research Use Only — Compliance Notice
The information on this page is intended for educational and informational purposes only. Tesamorelin (Tesamorelin) is a research compound sold for laboratory research purposes only. It has not been approved by the FDA for human use. Nothing on this page constitutes medical advice or is intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA. Consult a qualified healthcare professional before considering any peptide-related protocols.
